Targeted Lung Panel Now Available with Physician’s Order at Quest’s 2,200 Patient Service Centers Nationwide SECAUCUS, N.J. AND SAN DIEGO – December 1, 2021 – Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics
Spotlight Presentation at SABCS showed that in 38% of patients the HER2 status of the metastatic cancer differed from the primary tumor, offering new information to aid treatment decisions SAN DIEGO --(BUSINESS WIRE)--Dec. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular
SAN DIEGO --(BUSINESS WIRE)--Jan. 4, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held
SAN DIEGO --(BUSINESS WIRE)--Jan. 21, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.
SAN DIEGO --(BUSINESS WIRE)--Feb. 10, 2022-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer. With more than 30 years of healthcare experience,
SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W.
Ability to serially monitor treatment response, identify key biomarkers and customize assay aids clinical research efforts to improve treatment for metastatic cancers involving brain and spinal cord SAN DIEGO --(BUSINESS WIRE)--Feb. 22, 2022-- Biocept, Inc .
SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted an inducement stock option to purchase 134,550 shares of its common stock to Darrell Taylor , its new Senior Vice
Industry veteran to oversee operations for the company and its CNSide™ cerebrospinal fluid assay to aid in the management of patients with metastatic brain cancers SAN DIEGO --(BUSINESS WIRE)--Mar. 8, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products
SAN DIEGO --(BUSINESS WIRE)--Mar. 18, 2022-- Biocept, Inc. (Nasdaq: BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange Commission (SEC) on Thursday, March 31, 2022 .
